Canaquest Medical Corporation · OTC:CANQF
Canaquest Medical — Investor Presentation (April 2021)
21 slides from Canaquest Medical's investor presentation, April 2021
Slide 1: Corporate Presentation Q2 2021
Corporate Presentation Q2 2021
Slide 2: Forward Looking Statements
Forward Looking Statements To the extent of statements made in this presentation contains forward looking statements and information that are based upon beliefs of, and information currently available to, the company's management as well as estimates and assumptions made by the company’s management.
Slide 3: CanaQuest Medical Corp
CanaQuest Medical Corp LIFE SCIENCE/PHARMACEUTICAL COMPANY VISION To be a global leader in the formulation and development of health products from cannabis derivatives. C O N F I D E N T I A L & P R O P R I E TA R Y 3
Slide 4: Problem: Minimal Science Behind Medical Cannabis Products
Problem | Minimal Science Behind “Medical” Cannabis Products Today’s “medical” cannabis products take a trial-and-error approach to treating symptoms, rather than following a scientific method. Medical Cannabis without science is just Recreational Marijuana ❑ - Anecdotal evidence - doctors have no g
Slide 5: Opportunities: Two Master Formulations – Pharmaceutical Focus
Opportunities | Two Master Formulations – Pharmaceutical Focus Pharmaceutical Full pharmaceutical (Rx) product with FDA-certified healthcare claims (FDA approval required): Mentanine Rx – Treatment of Epilepsy Mentabinol Rx ❑ Dravet syndrome ❑ Multiple Sclerosis (MS) ❑ Lennox Gastaut syndrome ❑ Spas
Slide 6: Corporate Advantages: What Sets Us Apart From The Competition
Corporate Advantages | What Sets Us Apart From The Competition End-to-End Scientific Approach Partnerships - Processing & Distribution ❑ Western University, Dr. Steven Laviolette & 13 scientists – ❑ PurCann Pharma and SiliCycle - Signed agreement partners since 2017 ▪ Extensive experience and expert
Slide 7: Pharmaceutical Product: Comparison with Similar FDA Approved Product
Pharmaceutical Product | Comparison with Similar, FDA Approved Product Mentanine®Rx US$650/100ml¹ Epidiolex® Rx US$1,300/100ml Scientifically developed medicinal formula FDA-approved for epilepsy2 CBD 22.2 mg /ml, with Omega-3 active ingredients, flavor w/o sweetener CBD 100mg /ml, sesame as a carri
Slide 8: Competitive Advantages: Science Behind the Products
Competitive Advantages | Science Behind the Products Mentanine® Rx & Bypassing digestive Mentabinol® Rx system (nano emulsified) Delivered sublingually Other CBD & THC Damaging digestive (non nano emulsified) Delivered orally system C O N F I D E N T I A L & P R O P R I E TA R Y 8
Slide 9: Steps To FDA Approval
Steps To FDA Approval | Similar To Process With Health Canada Completed Pre-clinical Trials & Patented Master Formulations Agreement in place with BioPharma Global, engagement as consultants to initiate US-FDA, DIN application - expected shortly after completion of financing Seek Orphan Drug status,
Slide 10: ADC BioMedical Corp: Licensed Under Cannabis Act
ADC BioMedical Corp | Licensed Under Cannabis Act Mentanine® Sublingually applied with a Mentabinol® Sublingually delivered powder (Omega-3 + CBD) spray bottle (THC + L-Theanine) Omega-3 L- Theanine Compounds R E S U LT S 20mg of Mentanine® = 10× activation R E S U LT S 1mg of Mentabinol® = 10× effi
Slide 11: Mentanine: Is Not The CBD Oil Currently Sold In The Market
Mentanine® | Is Not The CBD Oil Currently Sold In The Market Mentanine® CBD + carrier oil (Omega-3 + CBD) (coconut, grapeseed, sesame… ) Omega-3 Carrier oil Compounds Crosses Blood Brain Barrier - Fast Stops At CB-2 Receptor R E S U LT S 20mg of Mentanine® = 10× More effective1 R E S U LT S 200mg of
Slide 12: Roadmap 2021: Near-Term Strategy After Completion Of Financing
Roadmap 2021 | Near-Term Strategy After Completion Of Financing 0-60 days 60-90 days 90-150 days 150+ days Mentanine® Mentanine® Mentanine® Mentanine® • E-commerce store launch • Establish Clinical Trials for • Canadian Distribution • Increase distribution (under Canada, Cannabis Epilepsy – Internat
Slide 13: Milestones And Associated Costs Of Reaching Them
Milestones | And Associated Costs Of Reaching Them • List on Canadian Stock Exchange • FDA submission for Mentanine Rx (legal & audit) (orphan drug status, 505(b)(2) • Revenue from e-commerce site regulatory pathway, breakthrough • Worldwide revenue from (Canada) therapy designation) Mentanine Rx, M
Slide 14: Mental Health Costs
Mental Health Costs Significant Mental Health Ailments to be Addressed $16 Trillion Mental Illness Will Cost the World $16 USD Trillion by 2030¹ $225 Billion Mental Health Costs in the US reached $225 USD Billion in 2019 - 5.5% of all health spending2 $50 Billion Mental Illness in Canada is at least
Slide 15: CBD Oil Market Size
CBD Oil Market Size Significant Potential For Revenue In CBD & Mental Health Markets $9.7 Billion Global CCBD Oil Market Size (2019) CAGR: 25.6% from 2020 – 2027¹ $6.4 Billion North America Cannabidiol Market Size (2019) CAGR: 27.7% from 2020 – 20272 Drivers: ▪ Medical and Wellness Purposes ▪ Favora
Slide 16: Pharmaceutical Regulatory Pathway To Market
Pharmaceutical Regulatory Pathway To Market | Patients Suffering from Epilepsy – Dravet & Lennox Gastaut Syndrome, and Tuberous Sclerosis Complex Total Addressable Market ~ 1.1M patients worldwide Serviceable Addressable Market 160,000 patients in US, Canada & EU Serviceable Obtainable Market 80,000
Slide 17: Market Capitalization - Comparable Companies
MARKET CAPITALIZATION - COMPARABLE COMPANIES Share Price Shares Market Company Name Pre-Revenue Profitable Symbol Market 02-April-21 Outstanding Capitalization 1.) GW Pharmaceuticals, PLC No No GWPH NASDAQ $ 217.26 31,266,348 $ 6,792,926,694 2.) Charlotte's Web Holdings Inc No No CWBHF OTCQX $ 4.53
Slide 18: Scientific Partners & Regulatory Advisors Team
Scientific Partners & Regulatory Advisors Team Dr. Steven Laviolette, B.Sc., Ph.D., a Professor and Neuroscientist in the Schulich School of Medicine & Dentistry at Western University, Addiction Research Group Dept. of Anatomy & Cell Biology, Dept. of Psychiatry R & D Program - 14 scientists http://
Slide 19: Scientific Partners (continued)
Scientific Partners (continued) | R & D Partnership Program – Pets (Dogs, Cats) Dr. David W.L. Ma, Ph.D. Professor, Department of Human Health and Nutritional Sciences, University of Guelph R & D Program - 5 scientists https://www.uoguelph.ca/hhns/people/dr-david-wl-ma Dr. Ma obtained his PhD in Med
Slide 20: Management & Patient Acquisition Team
Management & Patient Acquisition Team | 100+ Years of Management & Product Development Experience Richard Rusiniak, Mechanical Engineer, CEO, Director Over 35 years of management, design and process experience. Co-founder and former President, CFO, and CTO of Cymat Corp (TSX: CYM) with a market valu
Slide 21: Thank you
Thank you Contact Information: Paul Ramsay, President 416.704.3040 paul@canaquest.com www.canaquest.com 21
CanaQuest Medical — Investor Presentation (April 2021) on 6ix